Study of Liposomal Annamycin for the Treatment of Subjects With Soft-Tissue Sarcomas (STS) With Pulmonary Metastases
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, single-arm study that in Phase 1b will determine the
maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) and safety of L-Annamycin and
in Phase 2 will explore the efficacy of L- Annamycin as a single agent for the treatment of
subjects with STS with lung metastases for which chemotherapy is considered appropriate.